Checkpoint Inhibitors and SBRT for MCRPC

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Prostate Cancer MetastaticCastrate Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate Cancer Stage IV
Interventions
RADIATION

Stereotactic body radiotherapy

8 Gray x 3

DRUG

Ipilimumab Injection [Yervoy]

1 mg/kg IV Q3W for four doses,

DRUG

Nivolumab Injection [Opdivo]

Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W

PROCEDURE

Biopsies

From soft tissue metastases.

Trial Locations (1)

2730

Department of Oncology, Copenhagen University Hospital Herlev and Gentofte Hospital, Herlev

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Herlev and Gentofte Hospital

OTHER

NCT05655715 - Checkpoint Inhibitors and SBRT for MCRPC | Biotech Hunter | Biotech Hunter